Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Covidien Looks Strong Into the New Year


As the company continues to distance itself from its ex-parent, it could be a big winner in 2008.


A couple months ago, I wrote about the great opportunity in Covidien (COV), a manufacturer of medical products that was spun out of the Tyco (TYC) conglomerate in July. Yesterday, the company reported very healthy quarterly results as it continues to distance itself from its ex-parent, and I'm more confident than ever that this could be a big winner in 2008.

In the first report as a fully independent company, COV reported revenue rose 5% to $2.6 billion on robust sales of medical devices like laparoscopic surgery tools; equipment to diagnose and treat respiratory diseases; well as sutures, staples and other types of wound sealants.

Earnings came in at $34 million, or seven cents per share. This beat analysts' expectations, but were weighed down by restructuring expenses. That's very common with a spin-out, so I'm not worried about those. Also adding to expenses was expanded marketing initiatives aimed at building the Covidien name among medical professionals – a necessary but expensive activity. (Did you notice the Covidien sign on the outfield wall at Fenway Park during the World Series?)

Looking ahead to 2008, the company expects revenue to increase by 4% to 6%, to roughly $10.7 billion. This will be driven by sales of devices, pharmaceutical compounds, and imaging products. It is likely that Covidien will part with its retail sales segment, which manufactures generic diapers and other absorbent hygienic products, where growth prospects are fairly weak. By selling, Covidien will be able to invest in more lucrative business lines, which were largely neglected while under the Tyco corporate umbrella. Add it all up, and I'm still buying COV for a $55 target late next year.
< Previous
  • 1
Next >
Position in COV

The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.

Featured Videos